Press Releases
-
SK bioscience will establish an industry-university partnership to preemptively respond to new vira...2021. 12. 2 -
SK, IVI sign an agreement to launch the “Park MahnHoon Award” to honor individuals and organizations...2021. 11. 30 -
The first submission of a protein-based COVID-19 vaccine candidate in KoreaHigh expectations of the ...2021. 11. 15 -
The final data of the phase I/II clinical trial confirms 3.6 to 6 folds of neutralizing antibody tit...2021. 11. 05 -
SK bioscience will continue production of global biopharmaceutical company´s COVID-19 vaccines next...2021. 10. 06 -
The Korean-developed COVID-19 vaccine GBP510, is administered to phase 3 clinical trial subjects f...2021. 08. 30 -
- Phase I/II stage 1 confirms 5~8 folds of neutralizing antibody titer compared to human convalesce...2021. 08. 10 -
- GBP510, a COVID-19 vaccine candidate was submitted an IND for a Phase III clinical study in Korea ...2021. 06. 28 -
ESG Committee will review major management strategies related to the environment, society, and gove...2021. 06. 24 -
- SK bioscience invested about 150 billion KRW in the expansion of existing vaccine manufacturing p...2021. 06. 21 -
SK bioscience’s COVID-19 vaccine candidate, ‘GBP510’ secures up to 173.4 million USD of additional ...2021. 05. 24 -
SK bioscience’s Novavax’ COVID-19 vaccine candidate facility obtained GMP certification from the EMA...2021. 05. 17